Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DF 6002

Next Previous
Search
Drug Profile

DF 6002

Alternative Names: BMS-986415; DF-6002; IL-12 Fc - Dragnofly therapeutics

Latest Information Update: 10 Feb 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dragonfly Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Interleukin 12 replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 06 Feb 2023 Dragonfly Therapeutics owns all rights to the development of DF 6002
  • 01 Mar 2022 Dragonfly receives a milestone payment from Bristol Myers Squibb for progression of phase I DF6002-001 trial
  • 10 Apr 2021 Pharmacodynamics data from a priclinical trial in Solid tumours presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top